These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21180652)

  • 21. Molecule of the month. XOMA-052.
    Drug News Perspect; 2009 Oct; 22(8):497. PubMed ID: 20016858
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal function.
    Mayer M; Nudurupati S; Peng X; Marcinak J
    Drugs R D; 2014 Dec; 14(4):273-82. PubMed ID: 25374042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.
    Bertram LS; Black D; Briner PH; Chatfield R; Cooke A; Fyfe MC; Murray PJ; Naud F; Nawano M; Procter MJ; Rakipovski G; Rasamison CM; Reynet C; Schofield KL; Shah VK; Spindler F; Taylor A; Turton R; Williams GM; Wong-Kai-In P; Yasuda K
    J Med Chem; 2008 Jul; 51(14):4340-5. PubMed ID: 18588279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo pharmacokinetic study and oral glucose tolerance test of sulfoxide analogs of GPR40 agonist TAK-875.
    Yan Y; Xu Q; Zhao C; Dong H; Xu W; Zhang Y
    Drug Dev Res; 2020 Sep; 81(6):708-715. PubMed ID: 32359092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Discovery and development of a selective GPR40/FFAR1 agonist, fasiglifam, for treatment of type 2 diabetes mellitus].
    Tsujihata Y
    Nihon Yakurigaku Zasshi; 2014 Aug; 144(2):59-63. PubMed ID: 25109517
    [No Abstract]   [Full Text] [Related]  

  • 26. Deal watch: Metabolex and Sanofi-Aventis partner on GPCR agonists for type 2 diabetes.
    Nat Rev Drug Discov; 2010 Sep; 9(9):670. PubMed ID: 20811370
    [No Abstract]   [Full Text] [Related]  

  • 27. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
    Semple G; Lehmann J; Wong A; Ren A; Bruce M; Shin YJ; Sage CR; Morgan M; Chen WC; Sebring K; Chu ZL; Leonard JN; Al-Shamma H; Grottick AJ; Du F; Liang Y; Demarest K; Jones RM
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1750-5. PubMed ID: 22264481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CLX-0901 (Calyx Therapeutics).
    Barlocco D
    Curr Opin Investig Drugs; 2001 May; 2(5):650-3. PubMed ID: 11569941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Advances in the study of glucokinase and small molecule glucokinase activators].
    Li YQ; Feng ZQ; Song HR; Guo YS; Guo ZR
    Yao Xue Xue Bao; 2006 May; 41(5):390-4. PubMed ID: 16848312
    [No Abstract]   [Full Text] [Related]  

  • 30. [Diabetes mellitus type 2 the status of future therapy with GPR40 agonists].
    Verspohl EJ
    Med Monatsschr Pharm; 2014 Jul; 37(7):275. PubMed ID: 25065175
    [No Abstract]   [Full Text] [Related]  

  • 31. [Thiazolidenediones, diabetes and adipogenesis].
    Moreno L; Barettino D
    Med Clin (Barc); 1999 Apr; 112(12):457-8. PubMed ID: 10320960
    [No Abstract]   [Full Text] [Related]  

  • 32. [Reducing postprandial glucose levels. Glucosidase antagonists].
    Neye H
    Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecule of the month. Exenatide.
    Drug News Perspect; 2003 Nov; 16(9):621. PubMed ID: 14702143
    [No Abstract]   [Full Text] [Related]  

  • 34. Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus.
    Phillippe HM; Wargo KA
    Ann Pharmacother; 2010 Oct; 44(10):1615-23. PubMed ID: 20841518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin: an alternative treatment for noninsulin-dependent diabetes mellitus.
    Hitt CM
    Conn Med; 1995 Dec; 59(12):727-30. PubMed ID: 8821636
    [No Abstract]   [Full Text] [Related]  

  • 36. G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes.
    Bjenning C; Al-Shamma H; Thomsen W; Leonard J; Behan D
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1051-62. PubMed ID: 15535426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapeutic renaissance. Biguanides in type-2 diabetes: metformin].
    Neye H
    Pharm Unserer Zeit; 2002; 31(3):264-70. PubMed ID: 12071123
    [No Abstract]   [Full Text] [Related]  

  • 38. Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK-875).
    Lukin A; Bakholdina A; Zhurilo N; Onopchenko O; Zhuravel E; Zozulya S; Gureev M; Safrygin A; Krasavin M
    Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000275. PubMed ID: 33270252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
    Kang SU
    Drug Discov Today; 2013 Dec; 18(23-24):1309-15. PubMed ID: 24060477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Adverse effects of oral hypoglycemic drugs in elderly patients].
    Zakowska-Wachelko B
    Pol Tyg Lek; 1990 May 7-14; 45(19-20):389-91. PubMed ID: 2255657
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.